SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Mind Medicine (MindMed) Inc. MNMD NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • CA • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Analyst Price Target

Mind Medicine (MindMed) Inc. (MNMD) is a Biotechnology company in the Healthcare sector, currently trading at $20.69. It has a SharesGrow Score of 32/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Analyst consensus target is MNMD = $16 (-22.7% upside).

Net income is $184M (loss), growing at -61.7%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $332M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 6.29 (strong liquidity). Debt-to-assets is 0%. Total assets: $440M.

Analyst outlook: 1 / 1 analysts rate MNMD as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 10/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 40/100 (Fail), Future 64/100 (Pass), Income ?/100 (Fail).

$16.00

▼ 22.67% Downside

Average Price Target

The 12-month price target for Mind Medicine (MindMed) Inc. is $16.00.

MNMD SharesGrow Score Overview

39/100

SharesGrow Score

Below average — proceed with caution

View full scorecard →

VALUE 10/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 40/100

Gross margin is + market cap

FUTURE 64/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — MNMD

MNMD trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $16, implying -22.7% from the current price $21. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

MNMD: +0%/yr revenue is, -61.7%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet MNMD: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 6.29 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

MNMD: Gross margin is 0% (+0 pp trend), $2B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 1 analysts rate MNMD as buy (100%). Analyst consensus target is $16 (-22.7% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range4.7-21.08

Volume298.41K

Avg Volume (30D)2.53M

Market Cap$1.56B

Beta (1Y)2.62

Share Statistics

EPS (TTM)-2.06

Shares Outstanding$89.33M

IPO Date2016-11-15

Employees74

CEORobert Barrow

Financial Highlights & Ratios

EBITDA$-178.31M

Net Income$-183.79M

Operating Income$-166.31M

Total Cash$411.59M

Net Debt$-257.84M

Total Assets$440.1M

Price / Earnings (P/E)-10

Analyst Forecast

1Y Price Target$16.00

Target High$16.00

Target Low$16.00

Upside-22.7%

Rating ConsensusBuy

Analysts Covering1

Buy 100% Hold 0% Sell 0%

Price Target Summary

Company Info

CountryCA

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINCA24477V1058

Price Chart

MNMD

Mind Medicine (MindMed) Inc. ↗ · NASDAQ Capital Marke

Healthcare • Biotechnology

4.70 52WK RANGE 21.08

People Also View

Edgewise Therapeutics, Inc.

Kodiak Sciences Inc.

GH Research PLC

Atai Life Sciences N.V.

iTeos Therapeutics, Inc.

Checkpoint Therapeutics, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message